• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2026
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • PRODUCT LIBRARY

First Subjects Randomized in Clinical Trial Evaluating the Benefits of Total Segmental Fusion in Treating Degenerative Conditions in the Lumbar Spine

March 19, 2026 By SPINEMarketGroup

PLEASANTON, Calif., March 19, 2026 /PRNewswire/ — Providence Medical Technology, Inc., a pioneer in less invasive solutions for spine surgery, today announced enrollment of the first patients in its prospective, randomized controlled trial (RCT) evaluating the CORUS-LX System for the treatment of degenerative lumbosacral disease. This multi-center RCT will enroll subjects indicated for two-level interbody fusion with supplemental percutaneous pedicle screw fixation and posterior fusion. Subjects will be randomized to receive posterior fusion either with the CORUS-LX System or with the surgeon’s standard posterior fusion technique.

Dr. Kade Huntsman of the Huntsman Spinal Clinic in Salt Lake City, Utah, was the first clinical investigator to treat an enrolled subject with the study device. The case utilized a circumferential fusion approach, integrating lumbar interbody fusion with percutaneous pedicle screws and the CORUS-LX System for fusion bed preparation and supplemental posterior stabilization and fusion. Huntsman joins Dr. Mohsin Fidai and Dr. Vivek Mohan as early-enrolling investigators in the study, which aims to evaluate subjects through 2027.

The Lumbar Blueprint: Building on Insights from the FUSE Study
This study is designed to replicate the rigorous clinical validation established by Providence’s FUSE study, which was the largest prospective RCT to evaluate three-level cervical fusion. Evidence from FUSE demonstrated that adding CORUS PCSS to an anterior cervical fusion delivers clinically superior composite fusion rates to anterior fusion alone. This new trial seeks to provide similar high-level insights for the lumbar spine.

“The FUSE Study was a turning point for cervical spine surgery because it clearly demonstrated that tissue-sparing, supplemental posterior fixation improves patient outcomes for 3-level patients,” said Scott Lynch, Chief Product Officer of Providence Medical Technology. “We believe this new trial will demonstrate that the CORUS-LX System provides similar biological and mechanical advantages for the lumbar spine.”

A Superiority Trial
In a medical device market often focused on “non-inferiority,” Providence is pursuing a statistical superiority endpoint. The trial aims to establish a new benchmark for two-level lumbar treatment options by comparing a treatment arm (CORUS-LX + Interbody Fusion + Pedicle Screws) against the current gold standard (Interbody Fusion + Pedicle Screws alone). The hypothesis is that the CORUS-LX construct will be a superior option for patients requiring L4-S1 lumbar fusion. The primary endpoint is to demonstrate superior 12-month composite fusion rates, with additional data collection on patient-reported outcomes and return-to-work measures through 24 months.

New Technology Addresses Inadequate Fusion Bed Preparation
Percutaneous pedicle screws are commonly used to stabilize the spine as a part of lumbar fusion surgery. While they offer a less invasive approach, percutaneous pedicle screws can limit a surgeon’s ability to “decorticate” or prepare the bone for a solid fusion. The inability to thoroughly prepare the fusion bed can lead to higher rates of pseudarthrosis (failure to fuse), particularly in high-risk patients. Conversely, the CORUS-LX System provides a tissue-sparing solution that enables thorough decortication and precise bone graft delivery while providing the stability of a traditional screw. “Adding dedicated fusion implants in the facet joints provides more places for bones to fuse — both front and back of the spine,” said Dr. Huntsman. “We expect clinical results observed in the neck to extend to the lower back, with faster recovery and fewer fusion failures.”

Modernizing the Workflow: Precision via Surgical Navigation
A key component of the study involves using the CORUS-LX System with modern surgical workflows, specifically the surgical navigation systems from Medtronic and Globus Medical. By combining CORUS-LX with these leading navigation systems, surgeons can achieve high-precision placement of posterior implants through a tissue-sparing corridor.

About CORUS-LX
CORUS-LX is an integrated construct consisting of a stabilizer and two screws that is FDA-cleared for tissue-sparing posterior lumbar fusion and supplemental fixation. The system allows for extensive decortication and bone graft retention, serving as a dedicated fusion device that also provides significant stabilization.

About Providence Medical Technology, Inc.
Providence Medical Technology is a privately held medical device company focused on innovative solutions for cervical and lumbar spinal fusion. With a mission to improve clinical outcomes and reduce the economic burden of spine surgery, Providence is a leader in less-invasive, evidence-based surgical technologies. For more information, visit www.providencemt.com.

SOURCE Providence Medical Technology, Inc.

Related Posts:

  • Landmark Clinical Study Demonstrates Superiority of…
  • Providence Medical Technology Receives FDA 510(k)…
  • Providence Medical Technology Announces FDA…

Filed Under: NEWS Tagged With: 2026

Primary Sidebar

PLATINUM SPONSORS

EXALTA 2LOGO-min
GLOBAL biomedica
NORMED newLOGO-min
GENESYS SPINE
SPINEGUARD2025
Dymicron 2
GSMEDICAL2025
spinewaygroup
RUTHLESS SPINE
RUDISHAUER
NGMEDICAL
LfC
ispine
CENTINEL SPINE
TSUNAMI MEDICAL
syntropiq logo
A-SPINE
L&Kmodelo log

POPULAR POST LAST 90 DAYS

  • Globus Medical and Synaptive: Why the Rumors Deserve…
  • What Globus Medical Really Bought With Higgs Boson Health
  • BROCHURES
  • Globus Medical Announces Acquisition of Higgs Boson…
  • Neck and Neck: Is Globus Finally About to Overtake…
  • Who Runs DePuy Synthes? The CEO Fight That Killed…
  • Globus Medical to Showcase SCRIPT™ Patient-Specific…
  • J&J’s $21B DePuy Synthes Bet Could End in…
  • Federal Circuit Backs Globus Medical in Spinal…
  • Centinel Spine Files for NYSE IPO After 42% Jump in…
  • DePuy Synthes for Sale: Who Could Actually Buy the…
  • Forty Cervical Discs, One 3% Market: The Fight to…
  • COMPANIES
  • Do Spine Companies Really Need So Many Implants?…
  • Record Earnings, Discount Valuation: What Globus…
  • CD HORIZON® SOLERA™ System
  • New CFO, New AI Chief and a Patent Fight: What Is…
  • (UPDATED 2026) More Than 100 Options, No Single…
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • SYMPHONY Occipito-Cervico-Thoracic (OCT) System
  • Is DePuy Back in the Spine Fight? Why DePuy Really…
  • 3D-Printed Cages Are Everywhere. Has the Technology…
  • Thinking About a Spine Robot? Your 2026 Guide to the…
  • Top Expandable Cages of 2025: Which Lumbar Implants…
  • Highridge Medical CEO Departure: Spine’s…
  • What Is a Spine Hub, and Why Did Avesi Invest in New…
  • Whatever Happened to the Translational Cervical…
  • Posterior Cervical: The Segment Everyone Serves and…
  • CD Horizon Solera Voyager spinal system
  • Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
  • LAST 5 VIDEOS PUBLISHED

    1. SI-BONE: iFuse Granite Onyx™
    2. NovaSpine: DIVA Cervical
    3. Xenix Medical: Riva Modular Fixation System
    4. Spinal Elements: Overwatch® PCF
    5. Mighty Oak: Acorn 3D™

    Footer

    Contact us:

    spinemarketgroup@gmail.com info@thespinemarketgroup.com

    • LinkedIn
    • Twitter
    • YouTube

    PRIVACY POLICY

    • Legal
    • PRODUCT LIBRARY

    Copyright © 2026 · SPINEMarketGroup